Agenus Inc (AGEN) - Net Assets
Based on the latest financial reports, Agenus Inc (AGEN) has net assets worth $-227.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($186.46 Million) and total liabilities ($414.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AGEN intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-227.98 Million |
| % of Total Assets | -122.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -679.98% |
| 10-Year Change | N/A |
| Growth Volatility | 123.93 |
Agenus Inc - Net Assets Trend (1999–2025)
This chart illustrates how Agenus Inc's net assets have evolved over time, based on quarterly financial data. See AGEN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Agenus Inc (1999–2025)
The table below shows the annual net assets of Agenus Inc from 1999 to 2025. For live valuation and market cap data, see market value of Agenus Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-277.86 Million | +9.32% |
| 2024-12-31 | $-306.42 Million | -106.51% |
| 2023-12-31 | $-148.38 Million | -170.27% |
| 2022-12-31 | $-54.90 Million | -214.60% |
| 2021-12-31 | $47.91 Million | +122.65% |
| 2020-12-31 | $-211.50 Million | +8.58% |
| 2019-12-31 | $-231.34 Million | -32.54% |
| 2018-12-31 | $-174.55 Million | -130.22% |
| 2017-12-31 | $-75.82 Million | -93.77% |
| 2016-12-31 | $-39.13 Million | -155.32% |
| 2015-12-31 | $70.73 Million | +207.27% |
| 2014-12-31 | $23.02 Million | +613.68% |
| 2013-12-31 | $-4.48 Million | +62.72% |
| 2012-12-31 | $-12.02 Million | +42.30% |
| 2011-12-31 | $-20.83 Million | -41.64% |
| 2010-12-31 | $-14.71 Million | +13.36% |
| 2009-12-31 | $-16.98 Million | +29.03% |
| 2008-12-31 | $-23.92 Million | +49.18% |
| 2007-12-31 | $-47.06 Million | -170.56% |
| 2006-12-31 | $-17.39 Million | -154.53% |
| 2005-12-31 | $31.90 Million | -70.03% |
| 2004-12-31 | $106.44 Million | +1.14% |
| 2003-12-31 | $105.25 Million | +35.35% |
| 2002-12-31 | $77.76 Million | +2.41% |
| 2001-12-31 | $75.92 Million | -34.94% |
| 2000-12-31 | $116.70 Million | +125.73% |
| 1999-12-31 | $51.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Agenus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 214516500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $353.00K | % |
| Other Comprehensive Income | $-439.00K | % |
| Other Components | $1.91 Billion | % |
| Total Equity | $-271.11 Million | 100.00% |
Agenus Inc Competitors by Market Cap
The table below lists competitors of Agenus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reef Casino Trust
AU:RCT
|
$123.33 Million |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
$123.33 Million |
|
Tainergy Tech Co Ltd
TW:4934
|
$123.34 Million |
|
GR Silver Mining Ltd
V:GRSL
|
$123.37 Million |
|
Mincon Group plc
IR:MIO
|
$123.23 Million |
|
Reyon Pharmaceutical Co Ltd
KO:102460
|
$123.18 Million |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
$123.16 Million |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
$123.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Agenus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -326,380,000 to -271,111,000, a change of 55,269,000.
- Net income of 115,000 contributed positively to equity growth.
- Share repurchases of 87,000 reduced equity.
- New share issuances of 36,136,000 increased equity.
- Other comprehensive income increased equity by 959,000.
- Other factors increased equity by 18,146,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $115.00K | +0.04% |
| Share Repurchases | $87.00K | -0.03% |
| Share Issuances | $36.14 Million | +13.33% |
| Other Comprehensive Income | $959.00K | +0.35% |
| Other Changes | $18.15 Million | +6.69% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Agenus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $341.93 | $2.96 | x |
| 2000-12-31 | $567.93 | $2.96 | x |
| 2001-12-31 | $323.74 | $2.96 | x |
| 2002-12-31 | $283.57 | $2.96 | x |
| 2003-12-31 | $323.92 | $2.96 | x |
| 2004-12-31 | $285.85 | $2.96 | x |
| 2005-12-31 | $83.99 | $2.96 | x |
| 2006-12-31 | $-45.56 | $2.96 | x |
| 2007-12-31 | $-121.42 | $2.96 | x |
| 2008-12-31 | $-45.38 | $2.96 | x |
| 2009-12-31 | $-25.78 | $2.96 | x |
| 2010-12-31 | $-18.26 | $2.96 | x |
| 2011-12-31 | $-20.94 | $2.96 | x |
| 2012-12-31 | $-10.17 | $2.96 | x |
| 2013-12-31 | $-3.01 | $2.96 | x |
| 2014-12-31 | $7.70 | $2.96 | x |
| 2015-12-31 | $18.09 | $2.96 | x |
| 2016-12-31 | $-8.99 | $2.96 | x |
| 2017-12-31 | $-15.41 | $2.96 | x |
| 2018-12-31 | $-31.51 | $2.96 | x |
| 2019-12-31 | $-34.28 | $2.96 | x |
| 2020-12-31 | $-24.52 | $2.96 | x |
| 2021-12-31 | $4.19 | $2.96 | x |
| 2022-12-31 | $-3.90 | $2.96 | x |
| 2023-12-31 | $-8.29 | $2.96 | x |
| 2024-12-31 | $-15.20 | $2.96 | x |
| 2025-12-31 | $-9.12 | $2.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Agenus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.10%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-35.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -35.01% | -18100.00% | 0.00x | 1.08x | $-23.27 Million |
| 2000 | -40.04% | -10557.24% | 0.00x | 1.10x | $-58.40 Million |
| 2001 | -96.86% | -1614.51% | 0.05x | 1.23x | $-81.13 Million |
| 2002 | -71.86% | -1637.92% | 0.04x | 1.15x | $-63.65 Million |
| 2003 | -62.65% | -1481.76% | 0.03x | 1.33x | $-76.46 Million |
| 2004 | -52.76% | -7942.85% | 0.01x | 1.25x | $-66.81 Million |
| 2005 | -232.31% | -11762.88% | 0.01x | 3.27x | $-77.29 Million |
| 2006 | 0.00% | -7495.73% | 0.01x | 0.00x | $-50.14 Million |
| 2007 | 0.00% | -662.70% | 0.12x | 0.00x | $-32.09 Million |
| 2008 | 0.00% | -1082.49% | 0.05x | 0.00x | $-26.31 Million |
| 2009 | 0.00% | -909.36% | 0.07x | 0.00x | $-28.62 Million |
| 2010 | 0.00% | -652.05% | 0.11x | 0.00x | $-20.44 Million |
| 2011 | 0.00% | -844.63% | 0.14x | 0.00x | $-21.19 Million |
| 2012 | 0.00% | -70.95% | 0.46x | 0.00x | $-10.12 Million |
| 2013 | 0.00% | -987.62% | 0.09x | 0.00x | $-29.62 Million |
| 2014 | -184.58% | -608.94% | 0.09x | 3.24x | $-44.79 Million |
| 2015 | -124.25% | -354.12% | 0.10x | 3.42x | $-94.95 Million |
| 2016 | 0.00% | -562.60% | 0.14x | 0.00x | $-123.08 Million |
| 2017 | 0.00% | -281.48% | 0.31x | 0.00x | $-113.11 Million |
| 2018 | 0.00% | -434.14% | 0.27x | 0.00x | $-142.24 Million |
| 2019 | 0.00% | -71.75% | 0.97x | 0.00x | $-84.52 Million |
| 2020 | 0.00% | -205.19% | 0.41x | 0.00x | $-159.76 Million |
| 2021 | -49.94% | -8.09% | 0.63x | 9.73x | $-28.72 Million |
| 2022 | 0.00% | -224.51% | 0.24x | 0.00x | $-214.58 Million |
| 2023 | 0.00% | -157.22% | 0.50x | 0.00x | $-230.92 Million |
| 2024 | 0.00% | -219.61% | 0.46x | 0.00x | $-194.57 Million |
| 2025 | 0.00% | 0.10% | 0.50x | 0.00x | $27.23 Million |
Industry Comparison
This section compares Agenus Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Agenus Inc (AGEN) | $-227.98 Million | -35.01% | N/A | $123.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more